Previous Article | Next Article ![]()
Infection and Immunity, August 1999, p. 4223-4230, Vol. 67, No. 8
Whitehead Institute for Biomedical Research
and Department of Biology, Massachusetts Institute of Technology,
Cambridge, Massachusetts 021421;
Infectious Disease Unit, Massachusetts General Hospital,
Boston, Massachusetts 021142; Howard
Hughes Medical Institute and Department of Cell Biology, Vanderbilt
University Medical Center, Nashville, Tennessee
372323; Pulmonary Center, Boston
University School of Medicine, Boston, Massachusetts
021884; and Boston VA Medical Center,
Boston, Massachusetts 021305
Received 24 February 1999/Returned for modification 14 April
1999/Accepted 22 April 1999
Expression of the cytokine osteopontin (OPN) is elevated in
granulomas caused by Mycobacterium tuberculosis. We tested
the hypothesis that OPN contributes to host protection in a mouse model
of mycobacterial infection. When infected with Mycobacterium bovis BCG, mice lacking a functional OPN gene had more severe infections characterized by heavier bacterial loads and a delayed clearance of the bacteria. The OPN-null mice had greater granuloma burdens consistent with the elevated bacterial load. The ability of
osteopontin to facilitate the clearance of mycobacteria was most
pronounced early after infection and appeared to be independent of
known mediators of resistance to infection by mycobacteria: antigen-specific T-cell immunity, gamma interferon production, and
nitric oxide production. BCG grew more rapidly in macrophages derived
from OPN-null mice than in those from wild-type mice, demonstrating
that the null phenotype was due to an intrinsic macrophage defect.
These results indicate that osteopontin augments the host response
against a mycobacterial infection and that it acts independently from
other antimycobacterial resistance mechanisms.
Tuberculosis is a pandemic infection
that involves much of the world's population and is caused by
Mycobacterium tuberculosis. The World Health Organization
has raised concern over the epidemic potential of this organism because
of increasing antimicrobial resistance (36). Recently, an
isolate of M. tuberculosis with an extraordinary growth rate
and with increased rates of transmission was isolated (46).
These findings have generated interest in understanding the unique
interactions of host cells and mycobacteria: M. tuberculosis
can elude host immune responses and persist in a latent state for
years. The granuloma is a feature of this host-pathogen interaction.
Granulomas are characterized by a mononuclear cell infiltration of
macrophages and lymphocytes, by the formation of giant cells and
epithelioid cells, and by fibrosis, sometimes with calcification
(2, 12). The public health concerns and the unusual
pathology of tuberculosis led us to question what is normally involved
in the host macrophage response after infection by mycobacteria.
We have undertaken a study of macrophage gene expression changes after
infection by mycobacteria. By differential screening of a cDNA library
and probes derived from a murine macrophage cell line, one gene
isolate, osteopontin (OPN), was identified repeatedly in cells infected
by mycobacteria compared with cells infected by Escherichia
coli (35). We found that osteopontin gene expression in
human pulmonary macrophages increased after infection with virulent
M. tuberculosis and that OPN protein expression was
widespread in human tuberculosis pathology (35).
OPN is a secreted, phosphorylated, glycoprotein that is associated with
several host inflammatory states. The gene encoding OPN, known as
spp1, cosegregates with resistance to lethal infection by
Orientia (Rickettsia) tsutsugamushi in
mice (16, 23). The protein stimulates the migration of
macrophages (22, 34, 42) and of smooth muscle cells
(29, 51). OPN is found in the inflammatory macrophages of
rat myocardium after cryoinjury (33), in arterial atherosclerosis (21, 24), and in several granulomatous
conditions (3, 35). OPN has been labeled a cytokine based on
its proinflammatory properties (38, 45) and is a likely
candidate for mediating or modulating mononuclear cell infiltration and
chronic inflammation.
We and others have identified genes whose expression changes in
mammalian cells after infection (35, 52). These findings merit further studies to determine the roles of these genes in infection. The work detailed here describes the use of OPN knockout mice (28) to investigate whether OPN influences the host
response against infection by mycobacteria. Animals lacking OPN had
more severe infections and were delayed in eliminating the mycobacteria after infection. The findings identify a novel role for OPN as an
accessory molecule to activate macrophages and to augment the clearance
of inflammatory stimuli.
Animals.
OPN mutant mice (spp1tm1)
and wild-type controls 5 to 8 weeks old and matched for age and sex
were used for experiments. The generation of the OPN mutant mice has
been described elsewhere (28). The experiments described
herein were done with wild-type and mutant animals on a (129 × Black Swiss) hybrid background as was used previously (28).
Genotyping was confirmed on all breeding pairs with a PCR analysis. All
animal procedures were performed according to the guidelines of the
Massachusetts Institute of Technology Committee on Animal Care.
Infections.
Mycobacterium bovis bacillus
Calmette-Guérin (BCG) (ATCC 35734; Trudeau mycobacterial culture
collection no. 1011, "BCG Pasteur") was grown from a frozen stock
for 6 to 7 days (to an optical density at 600 nm of ~1.4) in
Middlebrook 7H9 broth with 0.5% glycerol, 0.05% Tween 80, and ADC
enrichment (Difco, Detroit, Mich.). On the day of infection, bacteria
were resuspended in phosphate-buffered saline (PBS), and an inoculum of
approximately 107 CFU was delivered intraperitoneally. This
route of inoculation was selected because of previous studies of OPN
and infection (23, 37) and because intraperitoneal
infections can successfully generate systemic mycobacterial infections
(32). At various times after infection, organs were
harvested for analysis. For CFU analysis, liver sections were weighed
and disrupted in PBS with an electric homogenizer (Polytron PT 1200B;
Kinimatica). Serial dilutions were made in 7H9 medium, and aliquots
were spread on 7H10 plates. CFU were enumerated 3 to 4 weeks later.
Immunohistochemistry.
Organs were harvested for histologic
analysis at the times indicated after infection. Tissues were fixed in
buffered formalin and processed by standard histologic techniques. For
immunohistochemistry, paraffin-embedded tissue sections were
deparaffinized in HistoClear (National Diagnostics, Atlanta, Ga.),
rehydrated in graded ethanol washes, and washed in PBS. The F4/80
antibody (Harlan Bioproducts, Indianapolis, Ind.) was used according to
the manufacturer's recommendations. Rabbit antiserum against holo-NOS2
(49) was a gift from Qiao-wen Xie and Carl Nathan and was
used as described previously (30), except that a 1:750
dilution was incubated with specimens at room temperature for 2 h.
Biotinylated secondary antibodies, avidin-biotin-horseradish peroxidase
conjugates, and substrates (Vector Labs, Burlingame, Calif.) were used
according to the manufacturer's directions. Slides were counterstained
with hematoxylin (Dako, Carpinteria, Calif.). After the completion of
staining, specimens were dehydrated in graded ethanol and ClearRite 3 (Richard-Allan Scientific, Kalamazoo, Mich.) before being mounted with
Permount (Fisher, Fair Lawn, N.J.).
Quantitation of granuloma burden.
The percent granuloma
burden, the total percentage of liver surface area covered by
granulomas, was measured by macrophage immunostaining and a Bioquant
image analysis system (Nashville, Tenn.) (26, 27). The
Bioquant system is an operator-interactive image analysis device linked
to stage x-y encoders, utilizing a Dage MTI CCD72 video camera system
with a Leitz Aristoplan microscope. A systematically random sampling
scheme was used to select fields for measurement of granuloma burden: a
grid was overlaid over the liver section, and from a random start
point, every eighth 500-µm by 500-µm field was captured by video
under a ×16 objective with the fluorescein cube. The counting chamber
consisted of a 500-µm by 500-µm sampling box with extended
exclusion lines. For each field, a threshold optical density was
obtained, which discriminated staining from background. Manual editing
of each field eliminated artifacts, as well as excluding granulomas
touching the lower and left borders of the counting chamber, while
including granulomas touching the upper and right borders. Granulomas
were defined as areas of immunoreactivity greater than 150 µm2, or greater than approximately two to three
macrophages. The total number of granulomas, the area of each
granuloma, and the sum of the areas of the granulomas divided by the
total area sampled (granuloma burden) were determined over four to five
liver sections for each animal. Some background counts could be
attributed to the confluence of Kupffer cells that registered above the
threshold filter. Statistical analysis was by t test
comparing homozygous spp1tm1 and wild-type mice.
The appropriateness of the sampling scheme was evaluated by calculating
the precision of the estimates, expressed as the coefficient of error
(CE) (48). The CE was <0.10, suggesting that a minimal
amount of variance in the granuloma burden measurement was from the
sampling technique and that measured differences reflected true
biological variability. All measurements were performed by a single
examiner (G.N.) blinded to treatment group.
In vitro cell stimulation.
Spleens were harvested at the
times indicated after infection and were crushed through nylon mesh to
obtain single-cell suspensions. Cells were washed and resuspended to
4 × 106 cells/ml, and 1 ml was plated per well of a
Falcon 24-well plate (Becton Dickinson, Lincoln Park, N.J.) with
various antigens or concanavalin A (ConA). The purified protein
derivative (PPD) from M. tuberculosis was generously donated
by Lederle Laboratories (Pearl River, N.Y.). Supernatants were
harvested 72 h later. The gamma interferon (IFN- NO measurement.
Peritoneal exudate cells (PEC) were isolated
5 to 7 days after intraperitoneal inoculation of 1 ml of 3%
thioglycolate. In some instances, macrophages were purified by
adherence and recovered by dispase treatment and scraping
(7). The production of nitric oxide (NO) by the PEC was
assessed by measuring the accumulation of nitrite in culture
supernatants. Griess reagents were used as described previously
(25).
In vitro assay of BCG growth.
The measurement of BCG growth
in macrophages was performed by using a [3H]uracil assay
that has been widely used to measure the growth of mycobacteria
(5, 17, 18, 40); uptake closely correlates with CFU
(17). Thioglycolate-derived PEC (2 × 105)
and BCG (multiplicity of infection, 5 to 10 bacteria per 1 macrophage) were cocultured with RPMI (Life Technologies, Gaithersburg, Md.) with
1% heat-inactivated fetal calf serum in U-bottom plates (ICN Biomedicals, Inc., Aurora, Ohio). After 4 h of coincubation, the wells were washed with warm Hank's balanced salt solution (Life Technologies) to remove extracellular BCG and nonadherent cells and
RPMI medium-1% fetal calf serum was added. At various times after the
infection, [3H]uracil was added to the wells, and after
18 h, the contents of the wells were harvested with a cell
harvester (Skatron, Inc., Sterling, Md.) by using Triton X-100 for
macrophage lysis and trichloroacetic acid.
Reduced clearance of M. bovis BCG in OPN-deficient
mice.
Wild-type and OPN-null mice were infected with BCG, and the
bacterial load in liver sections was assessed over 12 weeks by using
standard tissue staining for acid-fast bacilli. Four independent experiments were performed, and representative results are shown in
Fig. 1. When sections of liver and spleen
obtained 4 weeks after infection from wild-type mice were stained for
acid-fast organisms, few bacilli were detected (Fig. 1A and C). In
contrast, the mycobacteria were easily identified in the livers and
spleens of OPN-null animals (Fig. 1B and D). Similar results were seen in lung sections (data not shown).
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Attenuated Host Resistance against
Mycobacterium bovis BCG Infection in Mice Lacking
Osteopontin


![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
) MiniKit from
Endogen (Woburn, Mass.) was used to assay the culture supernatants.
![]()
RESULTS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References


View larger version (136K):
[in a new window]
FIG. 1.
Mycobacterial organism burden in tissues of OPN-null
mice after intraperitoneal infection with BCG. (A to D) Ziehl-Nielson
stains of liver (A and B) and spleen (C and D) from wild-type (A and C)
and spp1tm1 (B and D) animals. The mycobacteria
stain red. Similar findings were observed in 15 animals per genotype
from four different experiments. Original magnification, ×500. (E) CFU
determination from liver samples of animals infected intraperitoneally
at time 0 weeks. Symbols represent means ± standard errors for
three to four animals per group. A 10- to 40-fold difference in CFU
between wild-type and spp1tm1 animals at 4 weeks
was observed in three different experiments. P < 0.05
at 4 weeks postinfection. A similar 10-fold difference in CFU was also
observed in these animals' spleens at the 12-week time point.
Increase in granuloma number and size in OPN mutants. Several biological activities have been attributed to OPN that suggested it would be involved in granuloma formation: OPN is known to activate macrophage migration in vitro and in vivo (22, 34, 42), and it can bind calcium (6). However, histologic analyses of tissues after infection showed that granulomas were present in OPN-null animals; immunohistochemical analyses showed that these granulomas were comprised of both macrophages and T cells similar to those of the wild type (data not shown). The macrophage staining did indicate a difference in the total amount of hepatic tissue involved with granulomas. This difference was quantitated by measuring the granuloma burden. Liver sections stained for macrophages with the F4/80 monoclonal antibody and the Vector red alkaline phosphate substrate were subjected to a stereologic evaluation to measure the granuloma burden. The fluorescent emissions from the Vector red substrate clearly demonstrated that the OPN-null mice had more macrophages within the liver and overall a greater burden of granulomas (Fig. 2A). The granuloma burdens of liver specimens from 20 animals were systematically measured as described in Materials and Methods. The wild-type animals had an estimated 1.1% of the liver tissue area involved with granulomas (Fig. 2B). In contrast, the OPN-null mice had 3.1% of the liver tissue area involved with granulomas. Statistically significant differences were also observed when the sections were analyzed for the number of granulomas and the average granuloma size (Fig. 2B). The inability of OPN-null mice to clear BCG was reflected in more extensive granulomatous inflammation.
|
Macrophage recruitment in OPN-null mice. OPN induces inflammatory infiltrates when administered in vivo (42), and it is expressed rapidly after intraperitoneal administration of inflammatory stimuli (37). Because we used an intraperitoneal route of infection, it was possible that the elevated bacterial counts in spp1tm1 mice were a result of an early defect in inflammatory cell accumulation after inoculation. To test this possibility, we quantitated the acute inflammatory response after infection. Seventy-two hours is sufficient time to allow peak OPN gene expression after instillation of a peritoneal irritant (37). At this time after BCG inoculation, OPN-null mice unexpectedly had more cellular exudates than wild-type mice (Fig. 3A). To assess the specificity of this response, intraperitoneal injection of thioglycolate was used to elicit inflammatory cells. In repeated experiments, the PEC from spp1tm1 mice outnumbered those from wild-type mice (Fig. 3B). Cytospin and fluorescence-activated cell sorter analyses of the inflammatory exudates demonstrated there was an abundance of macrophages in PEC from both genotypes (data not shown). These results indicate that spp1tm1 mice did not have a defect in macrophage recruitment; in fact, these animals had a exaggerated inflammatory responses to peritoneal irritants.
|
IFN-
production and NO metabolism are normal in OPN-null
mice.
The production of IFN-
(9, 19) and reactive
nitrogen intermediates (RNI) (4, 5, 13, 30) is crucial to
the successful eradication of M. tuberculosis infections. It
was possible that the OPN-null mice were deficient in producing one or
both of these important factors after infection by BCG.
specifically after
stimulation with the relevant antigen, PPD. The level of IFN-
produced by splenocytes from null animals was comparable to that
produced by splenocytes from wild-type animals; this occurred when the difference between the CFU was the greatest. There was no difference in
the kinetics of induction of T-cell immunity, because splenocytes of
both genotypes produced similar levels of IFN-
1 week after infection (Fig. 4B). In addition, splenocytes from wild-type and OPN-null mice did not differ in their production of interleukin-4 (IL-4) or IL-10 after stimulation (data not shown). Therefore, the OPN
mutant mice mounted appropriate T-cell responses after infection. In
addition, there was not a defect in antigen presentation.
|
(14). Figure
5A shows the production of RNI by PEC
from wild-type and spp1tm1 mice treated with
inflammatory stimuli. Cells from both strains of mice produced
comparable RNI after stimulation by IFN-
plus lipopolysaccharide
(LPS) or plus tumor necrosis factor alpha (TNF-
).
|
Macrophages from OPN-null mice are defective in killing BCG. The presence of specific T-cell immunity (Fig. 4) and the apparently normal induction of NOS2 (Fig. 5) were consistent with the fact that OPN-null animals eventually reduce the numbers of BCG (Fig. 1E). It was possible, however, that there was a difference in the ability of the macrophages from spp1tm1 mice to limit the growth of the BCG in the absence of antigen-specific immunity. We tested the antimycobacterial activity of macrophages from naïve wild-type and null mice by infecting them with BCG in vitro. As shown in Fig. 6, [3H]uracil incorporation by BCG, which correlates directly with CFU (17), increased exponentially in macrophages derived from OPN-null mice. In contrast, the incorporation of [3H]uracil by BCG cultured with wild-type macrophages was linear throughout the experiment (Fig. 6). Thus, the OPN-null mice have an intrinsic defect in their macrophages that renders them more susceptible to BCG growth.
|
| |
DISCUSSION |
|---|
|
|
|---|
Resistance to tuberculosis in humans involves a complex network of activation signals and effector responses. The more primitive innate immune system relies on pattern recognition of a microorganism to initiate containment of a pathogen (15). Subsequently, initiation of the adaptive immune response enhances the eradication of M. tuberculosis via effector mechanisms such as macrophage activation (10) or direct cytotoxicity (44). The macrophage is a key participant in the innate response and in the effector phase of the adaptive response. Thus, understanding the interaction between macrophages and mycobacteria should help to identify novel host factors that influence resistance to this disease. Our previous analysis of changes in gene expression in macrophages after BCG infection identified one protein, OPN, whose expression was closely linked to tuberculosis infection. Our current studies with an OPN-null mouse demonstrate that OPN enhances host defenses against a mycobacterial infection.
Mice lacking a functional OPN gene suffered from more severe infections by M. bovis BCG than wild-type controls. The OPN-null animals had delayed eradication of live bacilli and exaggerated peritoneal inflammation. The spp1tm1 mice also had a greater hepatic granuloma burden, consistent with persistence of the bacilli and delayed resolution of the inflammation. The defect of the OPN-null mice is intrinsic to the macrophage and the cells' inability to control the growth of the mycobacteria.
Although it has been labeled a chemoattractant cytokine, OPN's role in the immune and inflammatory system has been the subject of much speculation. Intradermal injection of the protein can cause inflammation (22, 34, 42). Previous studies have shown that animals treated with anti-OPN serum have a macrophage migration defect (22, 50). In contrast, we found that OPN-null mice had more macrophages accumulate in response to thioglycolate or to an acute or a chronic mycobacterial infection. Similarly, there was no apparent difference in macrophage accumulation between wild-type and spp1tm1 animals after skin incision (28). While these findings do not exclude OPN as a chemoattractant molecule, it appears some stimuli, such as BCG, elicit signals that compensate for the absence of OPN and promote macrophage accumulation.
Rollo and colleagues have demonstrated an inhibitory activity of OPN on
NO production and cytotoxicity by macrophages in vitro (39).
The production of nitrite after stimulation with LPS and IFN-
was
delayed, a result of failed NOS2 mRNA induction (39). Our
studies of the OPN-null mice have not shown a gross abnormality of NO
metabolism. While OPN may inhibit NO production under certain conditions, our data indicate that, overall, OPN enhances the eradication of mycobacteria in vivo.
The data presented here, together with those of other studies (41), implicate OPN and its receptor, CD44, as cofactors in granulomatous inflammation. CD44 is believed to be one of several receptors for OPN (47). Mice deficient in CD44 have an exaggerated granulomatous response to intravenous Corynebacterium parvum (41). Likewise, the spp1tm1 mice had an increased granuloma burden after BCG infection. Thus, the phenotypes of the two mutant mice are similar: a 1.5- to 2-fold increase in granuloma size and number was observed in both null animals after a challenge with an agent that induces granuloma formation. A physiologic interaction of OPN with CD44 in granulomatous inflammation would explain the comparable phenotypes observed in both null mice.
The current data support a model in which the OPN-null mice have a defect in an important effector response of macrophages during a mycobacterial infection. OPN expression by macrophages is increased soon after a mycobacterial infection (35). We have now demonstrated that an OPN-null mutation creates an early defect in the eradication of mycobacteria in vivo and a defect in controlling BCG growth in vitro. These results are consistent with findings of reduced debridement of tissue wounds in the OPN-null mouse, probably due to poor macrophage function (28). Together with the observations with the CD44-null mouse described above, these data suggest that OPN enhances macrophage activity to degrade material taken up after phagocytosis, which would eradicate mycobacteria more efficiently.
Multiple factors, such as the production of inflammatory cytokines
(10, 11, 19, 20) and the production of NO (4, 30), are involved in host resistance to tuberculosis. Our present results indicate that OPN has a costimulatory role in macrophage activation to enhance the killing of mycobacteria by macrophages. A
similar model of accessory molecule stimulation of monocytes has been
suggested previously (31). Activation of human monocytes by
IFN-
is enhanced when the cells are cultured on fibronectin (31). In addition, interactions between several cell types
and the extracellular matrix can significantly increase the expression of chemokines (43). OPN, like fibronectin, contains an
arginine-glycine-aspartic acid (RGD) domain and may act as a soluble
protein (42) or may be cross-linked to extracellular matrix
proteins (1).
The goal of our initial investigation was to identify macrophage genes
whose expression was altered after infection by mycobacteria. The
current work confirms the biological relevance of the findings of the
genetic screen by identifying an active role of OPN in the clearance of
mycobacteria after infection. Further delineation of OPN's effects on
macrophages may lead to new strategies to treat infections, similar to
using IFN-
in patients with multidrug-resistant tuberculosis
(8).
| |
ACKNOWLEDGMENTS |
|---|
This work was supported by Public Health Service grants AI37869 (to R.A.Y.) and AI01305 (to G.J.N.). B.L.M.H., in whose laboratory the spp1-null mice were generated by L.L., is an Investigator of The Howard Hughes Medical Institute.
We thank Qiao-wen Xie and Carl F. Nathan (Cornell University Medical College, Department of Medicine) for providing the anti-holo-NOS2 reagent. The PPD was kindly provided by Patricia Van Zandt at Lederle Laboratories. We thank Michael C. Irizarry and Bradley T. Hyman (Massachusetts General Hospital, Department of Neurology) for assistance with the immunohistochemistry and stereologic procedures. We thank Sven Holder (Massachusetts General Hospital) and Margo Goetschkes (Boston VA Medical Center) for assistance with histology.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, MA 02142. Phone: (617) 258-5218. Fax: (617) 258-0376. E-mail: young{at}wi.mit.edu.
Present address: Center for Molecular Medicine, Maine Medical
Center Research Institute, South Portland, ME 04106.
Present address: Section of Pulmonary and Critical Care Medicine,
Yale University School of Medicine, New Haven, CT 06520.
Editor: S. H. E. Kaufmann
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Beninati, S.,
D. R. Senger,
E. Cordella-Miele,
A. B. Mukherjee,
I. Chackalaparampil,
V. Shanmugam,
K. Singh, and B. B. Mukherjee.
1994.
Osteopontin: its transglutaminase-catalyzed posttranslational modifications and cross-linking to fibronectin.
J. Biochem.
115:675-682 |
| 2. | Boros, D. 1978. Granulomatous inflammations. Prog. Allergy 24:183-267[Medline]. |
| 3. | Carlson, I., K. Tognazzi, E. J. Manseau, H. F. Dvorak, and L. F. Brown. 1997. Osteopontin is strongly expressed by histiocytes in granulomas of diverse etiology. Lab. Investig. 77:103-108[Medline]. |
| 4. | Chan, J., K. Tanaka, D. Carroll, J. Flynn, and B. R. Bloom. 1995. Effects of nitric oxide synthase inhibitors on murine infection with Mycobacterium tuberculosis. Infect. Immun. 63:736-740[Abstract]. |
| 5. |
Chan, J.,
Y. Xing,
R. S. Magliozzo, and B. R. Bloom.
1992.
Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages.
J. Exp. Med.
175:1111-1122 |
| 6. |
Chen, Y.,
B. S. Bal, and J. P. Gorski.
1992.
Calcium and collagen binding properties of osteopontin, bone sialoprotein, and bone acidic glycoprotein-75 from bone.
J. Biol. Chem.
267:24871-24878 |
| 7. | Coligan, J. E., A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, and W. Strober (ed.). 1994. Current protocols in immunology, 2nd ed., vol. 2. John Wiley & Sons, Inc., New York, N.Y. |
| 8. | Condos, R., W. N. Rom, and N. W. Schluger. 1997. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet 349:1513-1515[Medline]. |
| 9. |
Cooper, A. M.,
D. K. Dalton,
T. A. Stewart,
J. P. Griffin,
D. G. Russell, and I. M. Orme.
1993.
Disseminated tuberculosis in interferon gamma gene-disrupted mice.
J. Exp. Med.
178:2243-2247 |
| 10. | Cooper, A. M., and J. L. Flynn. 1995. The protective immune response to Mycobacterium tuberculosis. Curr. Opin. Immunol. 7:512-516[Medline]. |
| 11. |
Cooper, A. M.,
J. Magram,
J. Ferrante, and I. M. Orme.
1997.
Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with Mycobacterium tuberculosis.
J. Exp. Med.
186:39-45 |
| 12. |
Dannenberg, A. M., Jr., and G. A. W. Rook.
1994.
Pathogenesis of pulmonary tuberculosis: an interplay of tissue-damaging and macrophage-activating immune responses dual mechanisms that control bacillary multiplication., p. 459-484.
In
B. R. Bloom (ed.), Tuberculosis: pathogenesis, protection, and control. ASM Press, Washington, D.C.
|
| 13. | Denis, M. 1991. Tumor necrosis factor and granulocyte macrophage-colony stimulating factor stimulate human macrophages to restrict growth of virulent Mycobacterium avium and to kill avirulent M. avium: killing effector mechanism depends on the generation of reactive nitrogen intermediates. J. Leukoc. Biol. 49:380-387[Abstract]. |
| 14. | Ding, A. H., C. F. Nathan, and D. J. Stuehr. 1988. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J. Immunol. 141:2407-2412[Abstract]. |
| 15. | Fearon, D. T., and R. M. Locksley. 1996. The instructive role of innate immunity in the acquired immune response. Science 272:50-53[Abstract]. |
| 16. | Fet, V., M. E. Dickinson, and B. L. Hogan. 1989. Localization of the mouse gene for secreted phosphoprotein 1 (Spp-1) (2ar, osteopontin, bone sialoprotein 1, 44-kDa bone phosphoprotein, tumor-secreted phosphoprotein) to chromosome 5, closely linked to Ric (Rickettsia resistance). Genomics 5:375-377[Medline]. |
| 17. | Flesch, I., and S. H. Kaufmann. 1987. Mycobacterial growth inhibition by interferon-gamma-activated bone marrow macrophages and differential susceptibility among strains of Mycobacterium tuberculosis. J. Immunol. 138:4408-4413[Abstract]. |
| 18. |
Flesch, I. E.,
J. H. Hess,
I. P. Oswald, and S. H. Kaufmann.
1994.
Growth inhibition of Mycobacterium bovis by IFN-gamma stimulated macrophages: regulation by endogenous tumor necrosis factor-alpha and by IL-10.
Int. Immunol.
6:693-700 |
| 19. |
Flynn, J. L.,
J. Chan,
K. J. Triebold,
D. K. Dalton,
T. A. Stewart, and B. R. Bloom.
1993.
An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection.
J. Exp. Med.
178:2249-2254 |
| 20. | Flynn, J. L., M. M. Goldstein, J. Chan, K. J. Triebold, K. Pfeffer, C. J. Lowenstein, R. Schreiber, T. W. Mak, and B. R. Bloom. 1995. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2:561-572[Medline]. |
| 21. | Giachelli, C. M., N. Bae, M. Almeida, D. T. Denhardt, C. E. Alpers, and S. M. Schwartz. 1993. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J. Clin. Investig. 92:1686-1696. |
| 22. | Giachelli, C. M., D. Lombardi, R. J. Johnson, C. E. Murry, and M. Almeida. 1998. Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am. J. Pathol. 152:353-358[Abstract]. |
| 23. | Groves, M. G., D. L. Rosenstreich, B. A. Taylor, and J. V. Osterman. 1980. Host defenses in experimental scrub typhus: mapping the gene that controls natural resistance in mice. J. Immunol. 125:1395-1399[Abstract]. |
| 24. | Hirota, S., M. Imakita, K. Kohri, A. Ito, E. Morii, S. Adachi, H. M. Kim, Y. Kitamura, C. Yutani, and S. Nomura. 1993. Expression of osteopontin messenger RNA by macrophages in atherosclerotic plaques. A possible association with calcification. Am. J. Pathol. 143:1003-1008[Abstract]. |
| 25. |
Hwang, S. M.,
C. A. Lopez,
D. E. Heck,
C. R. Gardner,
D. L. Laskin,
J. D. Laskin, and D. T. Denhardt.
1994.
Osteopontin inhibits induction of nitric oxide synthase gene expression by inflammatory mediators in mouse kidney epithelial cells.
J. Biol. Chem.
269:711-715 |
| 26. | Hyman, B. T., K. Marzloff, and P. V. Arriagada. 1993. The lack of accumulation of senile plaques or amyloid burden in Alzheimer's disease suggests a dynamic balance between amyloid deposition and resolution. J. Neuropathol. Exp. Neurol. 52:594-600[Medline]. |
| 27. |
Irizarry, M. C.,
F. Soriano,
M. McNamara,
K. J. Page,
D. Schenk,
D. Games, and B. T. Hyman.
1997.
A deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse.
J. Neurosci.
17:7053-7059 |
| 28. | Liaw, L., D. E. Birk, C. B. Ballas, J. S. Whitsitt, J. M. Davidson, and B. L. M. Hogan. 1998. Altered wound healing in mice lacking a functional osteopontin gene (spp1). J. Clin. Investig. 101:1468-1478[Medline]. |
| 29. | Liaw, L., M. P. Skinner, E. W. Raines, R. Ross, D. A. Cheresh, S. M. Schwartz, and C. M. Giachelli. 1995. The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. J. Clin. Investig. 95:713-724. |
| 30. |
MacMicking, J. D.,
R. J. North,
R. La Course,
J. S. Mudgett,
S. K. Shah, and C. F. Nathan.
1997.
Identification of nitric oxide synthase as a protective locus against tuberculosis.
Proc. Natl. Acad. Sci. USA
94:5243-5248 |
| 31. |
McCarthy, J. B.,
B. V. Vachhani,
S. M. Wahl,
D. S. Finbloom, and G. M. Feldman.
1997.
Human monocyte binding to fibronectin enhances IFN-gamma-induced early signaling events.
J. Immunol.
159:2424-2430 |
| 32. | Murray, P. J., L. Wang, C. Onufryk, R. I. Tepper, and R. A. Young. 1997. T cell-derived IL-10 antagonizes macrophage function in mycobacterial infection. J. Immunol. 158:315-321[Abstract]. |
| 33. | Murry, C. E., C. M. Giachelli, S. M. Schwartz, and R. Vracko. 1994. Macrophages express osteopontin during repair of myocardial necrosis. Am. J. Pathol. 145:1450-1462[Abstract]. |
| 34. | Nasu, K., T. Ishida, M. Setoguchi, Y. Higuchi, S. Akizuki, and S. Yamamoto. 1995. Expression of wild-type and mutated rabbit osteopontin in Escherichia coli, and their effects on adhesion and migration of P388D1 cells. Biochem. J. 307:257-265. |
| 35. |
Nau, G. J.,
P. Guilfoile,
G. L. Chupp,
J. S. Berman,
S. J. Kim,
H. Kornfeld, and R. A. Young.
1997.
A chemoattractant cytokine associated with granulomas in tuberculosis and silicosis.
Proc. Natl. Acad. Sci. USA
94:6414-6419 |
| 36. | Pablos-Mendez, A., A. Laszlo, F. Bustreo, N. Binkin, D. L. Cohn, C. S. B. Lambregts-van Weezenbeek, S. J. Kim, P. Chaulet, P. Nunn, and M. C. Raviglione. 1997. Anti-tuberculosis drug resistance in the world. WHO/TB/97.229. World Health Organization, Geneva, Switzerland. |
| 37. |
Patarca, R.,
G. J. Freeman,
R. P. Singh,
F. Y. Wei,
T. Durfee,
F. Blattner,
D. C. Regnier,
C. A. Kozak,
B. A. Mock,
H. D. Morse, et al.
1989.
Structural and functional studies of the early T lymphocyte activation 1 (Eta-1) gene. Definition of a novel T cell-dependent response associated with genetic resistance to bacterial infection.
J. Exp. Med.
170:145-161 |
| 38. | Patarca, R., R. A. Saavedra, and H. Cantor. 1993. Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early T-lymphocyte activation-1/osteopontin gene. Crit. Rev. Immunol. 13:225-246[Medline]. |
| 39. | Rollo, E. E., D. L. Laskin, and D. T. Denhardt. 1996. Osteopontin inhibits nitric oxide production and cytotoxicity by activated RAW264.7 macrophages. J. Leukoc. Biol. 60:397-404[Abstract]. |
| 40. | Rook, G. A., J. Steele, L. Fraher, S. Barker, R. Karmali, J. O'Riordan, and J. Stanford. 1986. Vitamin D3, gamma interferon, and control of proliferation of Mycobacterium tuberculosis by human monocytes. Immunology 57:159-163[Medline]. |
| 41. |
Schmits, R.,
J. Filmus,
N. Gerwin,
G. Senaldi,
F. Kiefer,
T. Kundig,
A. Wakeham,
A. Shahinian,
C. Catzavelos,
J. Rak,
C. Furlonger,
A. Zakarian,
J. J. Simard,
P. S. Ohashi,
C. J. Paige,
J. C. Gutierrez-Ramos, and T. W. Mak.
1997.
CD44 regulates hematopoietic progenitor distribution, granuloma formation, and tumorigenicity.
Blood
90:2217-2233 |
| 42. |
Singh, R. P.,
R. Patarca,
J. Schwartz,
P. Singh, and H. Cantor.
1990.
Definition of a specific interaction between the early T lymphocyte activation 1 (Eta-1) protein and murine macrophages in vitro and its effect upon macrophages in vivo.
J. Exp. Med.
171:1931-1942 |
| 43. | Smith, R. E., C. M. Hogaboam, R. M. Strieter, N. W. Lukacs, and S. L. Kunkel. 1997. Cell-to-cell and cell-to-matrix interactions mediate chemokine expression: an important component of the inflammatory lesion. J. Leukoc. Biol. 62:612-619[Abstract]. |
| 44. | Stenger, S., and R. L. Modlin. 1998. Cytotoxic T cell responses to intracellular pathogens. Curr. Opin. Immunol. 10:471-477[Medline]. |
| 45. | Uede, T., Y. Katagiri, J. Iizuka, and M. Murakami. 1997. Osteopontin, a coordinator of host defense system: a cytokine or an extracellular adhesive protein? Microbiol. Immunol. 41:641-648[Medline]. |
| 46. |
Valway, S. E.,
M. P. C. Sanchez,
T. F. Shinnick,
I. Orme,
T. Agerton,
D. Hoy,
J. S. Jones,
H. Westmoreland, and I. M. Onorato.
1998.
An outbreak involving extensive transmission of a virulent strain of Mycobacterium tuberculosis.
N. Engl. J. Med.
338:633-639 |
| 47. | Weber, G. F., S. Ashkar, M. J. Glimcher, and H. Cantor. 1996. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 271:509-512[Abstract]. |
| 48. | West, M. J. 1993. New stereological methods for counting neurons. Neurobiol. Aging 14:275-285[Medline]. |
| 49. |
Xie, Q. W.,
H. J. Cho,
J. Calaycay,
R. A. Mumford,
K. M. Swiderek,
T. D. Lee,
A. Ding,
T. Troso, and C. Nathan.
1992.
Cloning and characterization of inducible nitric oxide synthase from mouse macrophages.
Science
256:225-228 |
| 50. | Yu, X. Q., D. J. Nikolic-Paterson, W. Mu, C. M. Giachelli, R. C. Atkins, R. J. Johnson, and H. Y. Lan. 1998. A functional role for osteopontin in experimental crescentic glomerulonephritis in the rat. Proc. Assoc. Am. Physicians 110:50-64[Medline]. |
| 51. | Yue, T. L., P. J. McKenna, E. H. Ohlstein, M. C. Farach-Carson, W. T. Butler, K. Johanson, P. McDevitt, G. Z. Feuerstein, and J. M. Stadel. 1994. Osteopontin-stimulated vascular smooth muscle cell migration is mediated by beta 3 integrin. Exp. Cell Res. 214:459-464[Medline]. |
| 52. |
Zhu, H.,
J. P. Cong,
G. Mamtora,
T. Gingeras, and T. Shenk.
1998.
Cellular gene expression altered by human cytomegalovirus: global monitoring with oligonucleotide arrays.
Proc. Natl. Acad. Sci. USA
95:14470-14475 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»